Molecular Markers in Sex Hormone Pathway Genes Associated with the Efficacy of Androgen-Deprivation Therapy for Prostate Cancer

Yu, Chia‐Cheng; Huang, Shu‐Pin; Huang, Chao-Yuan; Liu, Chia-Chu; Hour, Tzyh‐Chyuan; Huang, Ching‐Wen; You, Bang‐Jau; Chang, Ta-Yuan; Huang, Chun‐Hsiung; Bao, Bo‐Ying

doi:10.1371/journal.pone.0054627

Cited by 24 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This brings us to the third question being addressed in this review- can diagnostic tools identify aggressive PCa from non-aggressive PCa. It is recognized that aging cannot be reversed, but, genetic tests such as association of various clinical characteristics with single nucleotide polymorphisms (SNPs) can be used for early diagnosis and personalized treatment [12,98,99]. The use of prostate-specific antigen (PSA) levels in PCa diagnosis is still controversial [100].…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer: Is It a Battle Lost to Age?

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate Cancer: Is It a Battle Lost to Age?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Second, all the patients with PC in our study possessed an average age of 74 years and exhibited high mortality during follow-up (48.2% in the ADT group and 35.6% in the non-ADT group). Yu et al 33 reported that two genetic markers, namely, AKR1C3 rs12529 and AR-CAG repeat length, are significantly associated with PC-specific mortality. In addition, the genetic polymorphism of AKR1C3 rs12529 could also minimise ADT-related impact on quality of life in patients with PC 34.…”

Section: Discussionmentioning

confidence: 99%

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

Chiang

Huang

et al. 2017

BMJ Open

Self Cite

View full text Add to dashboard Cite

ObjectiveThis study investigated the risk of ischaemic bowel syndrome (IBS) in androgen deprivation therapy (ADT) users to explore the long-term outcomes of patients with prostate cancer (PC) receiving ADT treatment.MethodsWe performed a population-based retrospective cohort study. All the clinical information of the study participants were acquired from the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. We extracted data for all the patients newly diagnosed with prostate malignancy (ICD-9-CM 185 or C61 in ICD-10-CM) from 2000 to 2008. The patients were then divided into two groups: 7160 male ADT cohort receiving ADT and 7160 male non-ADT comparison group frequency matched by age and index year of ADT treatment of the ADT group. Cox proportional hazard regression was used to estimate the adjusted HR and 95% CIs of the IBS risk.ResultsNo significant difference was noted in the overall incidence rate for IBS between the ADT and non-ADT cohorts (0.86 and 0.89 per 1000 person–year, respectively, p=0.89). Even after adjusting for potential risk factors, a 1.06-fold risk of IBS (95% CI 0.62 to 1.82, p=0.82) was observed in the ADT cohort relative to the non-ADT cohorts. Moreover, we stratified the ADT cohort by time point of ADT treatment after PC diagnosis. Different IBS incidence rates were observed among the early ADT, late-ADT and non-ADT users at 0.77, 1.23 and 0.89 per 1000 person-years, respectively; nonetheless, the difference was not statistically significant. Moreover, no difference was found between the ADT treatment types and IBS risk, including sole orchiectomy, sole luteinising-hormone-releasing hormone and both.ConclusionsResults showed that ADT treatment in patients with PC is not an independent factor for IBS incidence. Large sample sizes for patients with IBS with patients with PC who had received ADT treatment are needed for further study.

show abstract

“…The association of clinicopathologic characteristics with time to BCR and PCSM was assessed using a log-rank test or Cox regression analysis. Multivariate Cox proportional hazard regression analysis was used to assess the effect of each SNP on clinical outcomes while adjusting for clinicopathologic variables, as previously described 27 29 30 31 32 33 34 35 . In the patient cohort with localized prostate cancer, explanatory variables included the known prognostic factors of age, PSA value at diagnosis, pathologic Gleason score, and tumor stage.…”

Section: Methodsmentioning

confidence: 99%

Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival

Bao

Lin

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

Ultraconserved regions (UCRs) are DNA segments of longer than 200 bp in length that are completely conserved between human, rat, and mouse genomes. Recent studies have shown that UCRs are frequently located at fragile sites involved in cancers, and their levels of transcription can be altered during human tumorigenesis. We systematically evaluated 14 common single-nucleotide polymorphisms (SNPs) within UCRs in three cohorts of prostate cancer patients, to test the hypothesis that these UCR SNPs might influence clinical outcomes. Examination using multivariate analysis adjusted for known clinicopathologic factors found association between rs8004379 and recurrence in localized disease [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.41–0.91, P = 0.015], which was confirmed in the replication set (HR 0.70, 95% CI 0.51–0.96, P = 0.027). Remarkably, a consistent association of rs8004379 with a decreased risk for prostate cancer-specific mortality was also observed in the advanced prostate cancer patient group (HR 0.48, 95% CI 0.32–0.70, P < 0.001). Additional in silico analysis suggests that rs8004379 tends to affect NPAS3 expression, which in turn was found to be correlated with patient prognosis. In conclusion, our findings suggest that SNPs within UCRs may be valuable prognostic biomarkers for assessing prostate cancer treatment response and survival.

show abstract

Molecular Markers in Sex Hormone Pathway Genes Associated with the Efficacy of Androgen-Deprivation Therapy for Prostate Cancer

Cited by 24 publications

References 38 publications

Prostate Cancer: Is It a Battle Lost to Age?

Prostate Cancer: Is It a Battle Lost to Age?

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival

Contact Info

Product

Resources

About